-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune checkpoint inhibitors significantly improve the prognosis of advanced melanoma.
Immune checkpoint inhibitors significantly improve the prognosis of advanced melanoma.
This study aims at the efficacy and safety of Pembrolizumab combined with Ipilimumab in the treatment of melanoma with PD1/PDL1 inhibitor failure.
This study aims at the efficacy and safety of Pembrolizumab combined with Ipilimumab in the treatment of melanoma with PD1/PDL1 inhibitor failure.
The study is an open-ended, single-arm, multi-center phase II study that included 70 patients with melanoma who had previously failed PD1/PDL1 inhibitor treatment.
The study is an open-ended, single-arm, multi-center phase II study that included 70 patients with melanoma who had previously failed PD1/PDL1 inhibitor treatment.
The study found that 20 patients (20/70, 29%) achieved clinical remission, including 5 patients with complete remission (7.
Clinical benefit
The median PFS was 5 months (95% CI, 2.
The median PFS was 5 months (95% CI, 2.
Progression-free time and duration of clinical response
87% (62/70) of the patients had any degree of treatment-related adverse events , the common ones were skin itching, rash, diarrhea, fatigue, nausea, and elevated transaminases .
87% (62/70) of the patients had any degree of treatment-related adverse events , the common ones were skin itching, rash, diarrhea, fatigue, nausea, and elevated transaminases .
Treatment-related adverse events
Treatment-related adverse eventsIn summary, this is the first prospective study on the application of Pembrolizumab combined with low-dose Ipilimumab after failure of PD1/L1 inhibitor treatment for melanoma.
In summary, this is the first prospective study on the application of Pembrolizumab combined with low-dose Ipilimumab after failure of PD1/L1 inhibitor treatment for melanoma.
Original source:
Original source:Daniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Daniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
J Clin Oncol.
2021 May 4; JCO2100079.
doi: 10.
1200/JCO.
21.
00079.
Online ahead of print .
in this message
